A practical reference on c-Met signaling: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-12-09. Anything still debated is marked as such rather than presented as settled.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
== Endogenous opioid peptides == There are three well-characterized families of opioid peptides produced by the body: enkephalins, β-endorphin, and dynorphins. The met-enkephalin peptide sequence is coded for by the enkephalin gene; the leu-enkephalin peptide sequence is coded for by both the enkephalin gene and the dynorphin gene. The proopiomelanocortin gene (POMC) also contains the met-enkephalin sequence on the N-terminus of β-endorphin, but the endorphin peptide is not processed into enkephalin.
=== Tuberous sclerosis complex === Sirolimus also shows promise in treating tuberous sclerosis complex (TSC), a congenital disorder that predisposes those afflicted to benign tumor growth in the brain, heart, kidneys, skin, and other organs. After several studies conclusively linked mTOR inhibitors to remission in TSC tumors, specifically subependymal giant-cell astrocytomas in children and angiomyolipomas in adults, many US doctors began prescribing sirolimus (Wyeth's Rapamune) and everolimus (Novartis's RAD001) to TSC patients off-label. Numerous clinical trials using both rapamycin analogs, involving both children and adults with TSC, are underway in the United States.
In 1966 the Johns Hopkins Gender Identity Clinic opened; it was one of the first in the US to provide care for transgender individuals, including hormone replacement therapy, surgery, psychological counseling, and other gender affirmative healthcare. The clinic required patients before a gender affirmation surgery to go through a program called "Real Life Test". The Real Life Test was a program where before a gender affirming surgery the patient was required to live with their desired gender role. In 1979 the clinic was closed by the newly appointed director of psychiatry Paul R. McHugh.
=== Evaluation of the Degree of Effectiveness of Biobeam Low Level Narrow Band Light on the Treatment of Skin Ulcers and Delayed Postoperative Wound Healing === The study conducted (in 1992) double blind clinical trial under regular hospital conditioned showed statistical significant results in the treatment with narrow band red light (660 nm) in comparison to placebo. It proved that low light narrow band has a significant role in the treatment of skin ulcers and delayed amputees and operative wounds.
Sources: en.wikipedia.org
In February 2026, during his State of the Union address to Congress, Trump was publicly criticized by Representatives Ilhan Omar and Rashida Tlaib, who challenged his immigration policies and accused his administration of harming U.S. citizens. In response, Trump posted on his social media platform Truth Social, suggesting that the lawmakers "should be sent back from where they came". Omar, a naturalized U.S. citizen born in Somalia, and Tlaib, a U.S.-born citizen of Palestinian descent, were both widely reported to have been the focus of these remarks. Media outlets and civil rights organizations described Trump's comments as xenophobic and controversial, drawing bipartisan criticism for targeting members of Congress based on their heritage.
The secret behind a spider web's stickiness lies in the tiny glue droplets dotting its silk threads. Orb-weaver spiders, such as Larinioides cornutus, coat their silk with a special hygroscopic substance that keeps the glue soft and tacky by drawing in water from the air. This built-in humidity control prevents the adhesive from drying out too quickly. The hardening of the viscoelastic protein is indirectly controlled by changes in water content, which in turn affect the concentration of the ionic liquid. As this balance shifts, the glue's viscosity adjusts, helping the web maintain its grip on captured prey. The web is electrically conductive which causes the silk threads to spring out to trap their quarry, as flying insects tend to gain a static charge which attracts the silk. Neurotoxins have been detected in the glue balls of some spider webs. Presumably these toxins help immobilize prey, but their function could also be antimicrobial, or protection from ants or other animals that steal from the webs or might attack the spider. Spider silk has greater tensile strength than the same weight of steel and much greater elasticity. Its microstructure is under investigation for potential applications in industry, including bullet-proof vests and artificial tendons. Researchers have used genetically modified mammals and bacteria to produce the proteins needed to make this material.
== Production == Optimer ligands are produced via solid-phase synthesis. Solid-phase chemical synthesis was invented in the 1960s by Robert Bruce Merrifield, for which he was awarded the Nobel Prize for Chemistry in 1984. Solid-phase synthesis is carried out on a solid support held between filters, in columns that enable all reagents and solvents to pass through freely. Solid-phase synthesis has a number of advantages over cell-based manufacturing that is typically used for protein affinity reagents, such as antibodies:
=== General === A 2020 study of data from 1999 to 2015 suggests that children living with married parents tended to have lower rates of early-life mortality than those living with unmarried or single parents and non-parents.
Myoepithelioma of the head and neck – A (usually) benign tumor of the head/neck consisting of solely myoepithelial cells. Epithelial-myoepithelial carcinoma (of the salivary glands) – A low-grade malignant tumor composed of both neoplastic epithelial and neoplastic myoepithelial cells (a biphasic tumor). Epithelial-myoepithelial carcinoma of the lung – A malignant tumor composed of both epithelial and myoepithelial tissues whose pathology resemble salivary cells. Adenomyoepithelioma of the breast – A (usually) benign tumor of the breast composed of Myoepithelial and Adeno (glandular) cells. Myoepithelioma of the breast – A usually benign or exceedingly rare malignant tumor which mimics IDC but with cells resembling adenoid cysts. If malignant, this is also known as a Myoepithelial carcinoma.
Sources: en.wikipedia.org
Sabo DJ, Orlando JA (1968). "Isolation, purification, and some properties of reduced nicotinamide adenine dinucleotide phosphate-cytochrome C2 reductase from Rhodopseudomonas spheroides". J. Biol. Chem. 243 (13): 3742–9. doi:10.1016/S0021-9258(19)34201-2. PMID 4385431.
==== Kino-Pravda ==== Dziga Vertov was central to the Soviet Kino-Pravda (literally, "cinematic truth") newsreel series of the 1920s. Vertov believed the camera – with its varied lenses, shot-counter shot editing, time-lapse, ability to slow motion, stop motion and fast-motion – could render reality more accurately than the human eye, and created a film philosophy from it.
== Uses == In the 1970s and 1980s, the proportionately largest use of these polymers was in water treatment. The next major application by weight is additives for pulp processing and papermaking. About 30% of polyacrylamide is used in the oil and mineral industries.
They finished second behind Manchester United however, losing their slender advantage once they lost their penultimate match. United also eliminated Arsenal in a FA Cup semi-final replay after extra time; Wenger afterwards said: "it was a smashing game, and in the end, the luckiest won." In August 1999, Anelka joined Real Madrid, having threatened to strike if Arsenal did not grant him a move abroad. Wenger used a portion of the proceeds generated through the Anelka sale to fund the build of the Arsenal Training Centre, expressing his desire to establish a "home away from Arsenal". He renewed his forward line by signing Davor Šuker from Real Madrid, and Thierry Henry, who joined after seven "injury-interrupted" months at Juventus for £11.5 million. It was Wenger's intention to partner Anelka with Henry, but the former's departure meant the plan was scrapped. The following seasons were comparatively barren. Arsenal again exited the Champions League at the group stage, but dropped down to the UEFA Cup. Wenger guided his team to the final, where they lost to Galatasaray on penalties. In the league, Arsenal finished 18 points behind Manchester United as runners-up, and though they closed the gap to eight points in 2000–01, they never posed a serious title challenge. The trophy drought continued past 2001, when Michael Owen scored two late goals for Liverpool to beat Arsenal in the FA Cup Final. Wenger rued his team's inability to make possession count, but refused to blame individuals, namely Henry, for missing chances.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
Published human trials are lacking. Most evidence comes from laboratory and animal studies. Therefore, human benefits and risks are not established.